背景:尽管咖啡消费在世界范围内普遍存在,最近的一项研究表明,咖啡因的急性摄入会对习惯性咖啡因消费者的n-back任务的工作记忆(WM)表现产生负面影响。然而,缺乏双盲,使用空间跨度任务评估咖啡因的空间WM(SWM)效应的安慰剂对照研究。因此,本研究旨在检查急性咖啡因给药的效果(200毫克,PO)关于习惯性咖啡因消费者的SWM和口头WM(VWM)。
方法:咖啡因对工作记忆(WM)的影响是通过在延迟依赖的条件下(0、4、8和6s),双盲,安慰剂对照研究,包括18名健康参与者。这些数据来自我们之前发表的研究。获得的总分和达到的最高分数是研究的主要结果变量。
结果:咖啡因对SWM有重大影响(获得的最大值,p=0.013;总分,p=0.007)以与延迟无关的方式。然而,咖啡因对VWM没有显著的主要影响(获得的最大值p=0.82,总评分p=0.56)。
结论:总体而言,本研究发现与咖啡因改善认知能力的普遍看法相矛盾,并提示在习惯性饮用咖啡/茶的人群中,急性摄入咖啡因可能会损害SWM.
背景:CT-2018-CTN-02561(治疗用品管理临床试验注册中心)和ACTRN12618001292268(澳大利亚新西兰临床试验注册中心)。
BACKGROUND: Although coffee consumption is widespread worldwide, a recent study showed that acute intake of caffeine negatively affects working memory (WM) performance on n-back tasks among habitual caffeine consumers. However, there is a scarcity of double-blind, placebo-controlled studies that assess the spatial WM (SWM) effects of caffeine using spatial span tasks. Therefore, the present study aimed examine the effects of acute caffeine administration (200 mg, PO) on SWM and verbal WM (VWM) among habitual caffeine consumers.
METHODS: The effects of caffeine on working memory (WM) was evaluated through the administration of backward digit span and spatial span tasks under a delay-dependent condition (0, 4, 8, and 6 s) in a randomized, double-blind, placebo-controlled study involving 18 healthy participants. This data is derived from our previous published study. The total scores obtained and the maximum scores achieved were the primary outcome variables of the study.
RESULTS: Caffeine had a significant impact on SWM (maximum obtained, p = 0.013; for total scored, p = 0.007) in a delay-independent manner. However, there were no significant main effects of caffeine on VWM (p = 0.82 for maximum obtained, p = 0.56 for total scored).
CONCLUSIONS: Overall, the present findings contradict the commonly held belief that caffeine improves cognitive performance and suggest that acute administration of caffeine may impair SWM in habitual coffee/tea drinkers.
BACKGROUND: CT-2018-CTN-02561 (Therapeutic Goods Administration Clinical Trial Registry) and ACTRN12618001292268 (The Australian New Zealand Clinical Trials Registry).